Improved response to infliximab after leukocytapheresis in a patent with rheumatoid arthritis

Modern Rheumatology

Volumn 17, Issue 3, 2007, Pages 253-255

  Azuma, Teruhisa ^a,b   Ishimaru, Hiroyasu ^a   Hatta, Kazuhiro ^a   Kori, Yoshiaki ^a  

^a TENRI HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acquired resistance; Infliximab(IFM); Leukocytapheresis (LCAP); Rheumatoid arthritis

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; CYCLOSPORIN A; INFLIXIMAB; METHOTREXATE; NAFAMSTAT MESILATE; PREDNISOLONE; RHEUMATOID FACTOR; STROMELYSIN;

ADULT; ARTHROCENTESIS; ARTICLE; BONE EROSION; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPANESE; JOINT SWELLING; LEUKAPHERESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKAPHERESIS;

EID: 34250623681     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-007-0576-9     Document Type: Article

References (8)

1. Y Ueki Y Yamasaki T Kanamoto T Kawazu M Yano K Matsumoto 2000 Evaluation of filtration leukocytapheresis for use in the treatment of patients with rheumatoid arthritis Rheumatology 39 165-71 10725066 10.1093/ rheumatology/39.2.165 1:STN:280:DC%2BD3c7ptVSnsA%3D%3D
2. T Hidaka K Suzuki Y Matsuki M Takamizawa-Matsumoto K Kataharada T Ishizuka 1999 Filtration leukocytapheresis therapy in rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial Arthritis Rheum 42 431-7 10088764 10.1002/ 1529-0131(199904)42:3<431::AID-ANR6>3.0.CO;2-2 1:STN:280:DyaK1M7os1Khtw%3D%3D
3. K Kempe H Tsuda K Yang K Yamaji Y Kanai H Hashimoto 2004 Filtration leukocytapheresis therapy in the treatment of rheumatoid arthritis patients resistant to or failed with methotrexate Ther Apher Dial 8 197-205 15154871 10.1111/j.1526-0968.2004.00132.x 1:CAS:528:DC%2BD2cXmtlSlurw%3D
4. MH Buch PG Conaghan MA Quin SJ Bingham D Veale P Emery 2004 True infliximab resistance in rheumatoid arthritis: A role for lymphotoxin α? Ann Rheum Dis 63 1344-6 15033655 10.1136/ard.2003.014878 1:STN:280:DC%2BD2cvoslShsQ%3D%3D
5. A Martinez M Salido G Bonilla D Pascual-Salcedo M Fernandez-Arquero S Miguel 2004 Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients Arthritis Rheum 50 1077-82 15077289 10.1002/art.20154 1:CAS:528:DC%2BD2cXjslGqsrY%3D
6. EW St Clair CL Wagner AA Fasanmade B Wang T Schaible A Kavanaugh 2002 The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 1451-9 12115174 10.1002/art.10302 1:CAS:528:DC%2BD38Xltlantbc%3D
7. R Van Vollenhoven A Harju S Brannemark L Klareskog 2003 Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense Ann Rheum Dis 62 1195-8 14644858 10.1136/ard.2003.009589 1:CAS:528:DC%2BD2cXit1Wntw%3D%3D
8. Y Izumi M Tominaga N Iwanaga M Huang F Tanaka K Aratake 2006 Twenty-four-week follow-up examination of a leukocytapheresis therapy in rheumatoid arthritis Mod Rheumatol 16 20-3 16622719 10.1007/ s10165-005-0448-0